Edsmyr F, Andersson L, Esposti P L
Urology. 1984 Mar;23(3 Suppl):51-3. doi: 10.1016/s0090-4295(84)80117-x.
In our investigation of different chemotherapy protocols, the best results in recent years were obtained with a combination of cisplatinum and doxorubicin in patients with recurrent urinary bladder cancer. This applied both to the local bladder tumor and the metastases. With respect to the cases of advanced localized bladder cancer, refined surgery or more developed equipment in radiotherapy, even developing new particles or rays, presumably will give only marginal effects on eradication of the tumor. A new approach may be to give a combined therapy of CDDP and doxorubicin before surgery and/or radiotherapy; a pilot study is going on in Stockholm. Experience so far has shown that CDDP together with radiotherapy or after preoperative irradiation followed by cystectomy is not tolerable to the patients. Between 40 and 50 per cent of them failed to fulfill the treatment.
在我们对不同化疗方案的研究中,近年来复发性膀胱癌患者使用顺铂和阿霉素联合治疗取得了最佳效果。这在局部膀胱肿瘤和转移瘤方面均适用。对于晚期局限性膀胱癌病例,精细的手术或放疗中更先进的设备,甚至开发新的粒子或射线,大概对肿瘤根除只能产生微不足道的效果。一种新的方法可能是在手术和/或放疗前给予顺铂和阿霉素联合治疗;斯德哥尔摩正在进行一项试点研究。迄今为止的经验表明,顺铂与放疗联合使用,或术前放疗后行膀胱切除术,患者无法耐受。其中40%至50%的患者未能完成治疗。